Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTS109 in Relapsing/Refractory Autoimmune Diseases
NCT07236801Phase 1Recruiting
- Sponsor
- China Immunotech
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of YTS-109 in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's syndrome and 3 more, sponsored by China Immunotech. Primary endpoint: Treatment-Emergent Adverse Events at 52 weeks. Started Nov 2025; status: recruiting.
02
Drugs
YTS-109
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)Sjögren's syndromeinflammatory myopathy (IIM)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT07236801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07236801.